Development of MK-4827: A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors

被引：0
|
作者：
Jones, Philip [1 ]
Altamura, Sergio [1 ]
Boueres, Julia [1 ]
Ferrigno, Federica [1 ]
Fonsi, Massimiliano [1 ]
Gavory, Gerald [1 ]
Giomini, Claudia [1 ]
Koch, Uwe [1 ]
Lamartina, Stefania [1 ]
Monteagudo, Edith [1 ]
Ontoria, Jesus M. [1 ]
Roscilli, Giuseppe [1 ]
Rowley, Michael [1 ]
Scarpelli, Rita [1 ]
Schultz-Fademrecht, Carsten [1 ]
Toniatti, Carlo [1 ]
机构：
[1] IRBM Merck Res Labs Rome, I-00040 Pomezia, Italy
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2009年 / 238卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
220-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Development of MK-4827: a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors
    Jones, Philip
    Altamura, Sergio
    Ferrigno, Federica
    Fonsi, Massimiliano
    Gavory, Gerald
    Giomini, Claudia
    Lamartina, Stefania
    Lazzaro, Domenico
    Mesiti, Giuseppe
    Monteagudo, Edith
    Mori, Federica
    Ontoria, Jesus
    Roscilli, Giuseppe
    Scarpelli, Rita
    Rowley, Michael
    Toniatti, Carlo
    CANCER RESEARCH, 2009, 69
  • [2] Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors
    Jones, Philip
    Altamura, Sergio
    Boueres, Julia
    Ferrigno, Federica
    Fonsi, Massimiliano
    Giomini, Claudia
    Lamartina, Stefania
    Monteagudo, Edith
    Ontoria, Jesus M.
    Orsale, Maria Vittoria
    Palumbi, Maria Cecilia
    Pesci, Silvia
    Roscilli, Giuseppe
    Scarpelli, Rita
    Schultz-Fademrecht, Carsten
    Toniatti, Carlo
    Rowley, Michael
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) : 7170 - 7185
  • [3] Poly (ADP-Ribose) Polymerase Inhibitor MK-4827 together with Radiation as a Novel Therapy for Metastatic Neuroblastoma
    Mueller, Sabine
    Bhargava, Samhita
    Molinaro, Annette M.
    Yang, Xiaodong
    Kolkowitz, Ilan
    Olow, Aleksandra
    Wehmeijer, Noor
    Orbach, Sharon
    Chen, Justin
    Matthay, Katherine K.
    Haas-Kogan, Daphne A.
    ANTICANCER RESEARCH, 2013, 33 (03) : 755 - 762
  • [4] MK-4827, a novel poly(ADP-ribose) polymerase (PARP) inhibitor, radiosensitizes non-small cell lung cancer (NSCLC) cells
    Jensen, Kathleen
    Gavory, Gerald
    Toniatti, Carlo
    Meyn, Raymond
    CANCER RESEARCH, 2009, 69
  • [5] Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells
    Bridges, Kathleen A.
    Toniatti, Carlo
    Buser, Carolyn A.
    Liu, Huifeng
    Buchholz, Thomas A.
    Meyn, Raymond E.
    ONCOTARGET, 2014, 5 (13) : 5076 - 5086
  • [6] First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 with antitumour activity in advanced BRCA-deficient and sporadic cancers
    Garcia, V. M. Moreno
    Wilding, G.
    Sandhu, S. K.
    Schelman, W. R.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Kreischer, N.
    Carpenter, C.
    Molife, L. R.
    Kaye, S.
    de Bono, J. S.
    Wenham, R. M.
    ANNALS OF ONCOLOGY, 2011, 22 : 39 - 39
  • [7] PHASE I STUDY OF A POLY(ADP)-RIBOSE POLYMERASE (PARP) INHIBITOR MK-4827 (MK) WITH ANTITUMOUR ACTIVITY IN SPORADIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)
    Sandhu, S. K.
    Moreno, V.
    Wilding, G.
    Omlin, A.
    Schelman, W. R.
    Miranda, S.
    Riinaes, R.
    Hylands, L.
    Attard, G.
    Cassidy, A.
    Kreischer, N.
    Carpenter, C.
    Demuth, T.
    Wenham, R. M.
    de-Bono, J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 33 - 33
  • [8] First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.
    Sandhu, S. K.
    Wenham, R. M.
    Wilding, G.
    McFadden, M.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Carpenter, C. L.
    De Bono, J. S.
    Schelman, W. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
    Schelman, W. R.
    Sandhu, S. K.
    Garcia, V. Moreno
    Wilding, G.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Kreischer, N.
    Carpenter, C. L.
    Molife, L. R.
    Kaye, S. B.
    De Bono, J. S.
    Wenham, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Identification of a novel efficacious and safe poly (ADP-ribose) polymerase (PARP) and tankyrase inhibitor for treatment of various types of solid tumors
    Jain, M.
    Chatterjee, A.
    Mohapatra, J.
    Bandhyopadhyay, D.
    Ghoshdostidar, K.
    Bhatnagar, U.
    Patel, H.
    Srivastava, B.
    Ramanathan, V.
    Patel, P.
    Desai, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S63 - S63
12345